Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
MR is strongly recommended as a means of prioritizing drug targets for cardiovascular research, to avoid expensive failures in phase III randomized controlled trials (RCTs) [18, 19] and to identify mechanistic targets of intervention, complementary to RCTs [19]
Weina H, Yuhu N, Christian H, Birong L, Feiyu S, Le W
Notice & Disclaimer This product is intended for laboratory and research use only
Key Takeaways Dosage, protein, and movement are the big three levers for breaking an Ozempic plateau
Acknowledgements This research was funded by the Swedish Research Council (20142945 to KPS and 20137107 to PR), Novo Nordisk Foundation Excellence project grant (to KPS), Ragnar Sderberg Foundation (to KPS), Harald Jeanssons Stiftelse and Greta Jeanssons Stiftelse (to KPS), Magnus Bergvalls Stiftelse (to KPS), Wallenberg Foundation and Center for Molecular and Translational Medicine (to KPS) and National Institute of Health NIH-DK096139 (to MRH) and NIH-DK104897 (to SEK)
US$ 28.87
US$ 23.89
US$ 28.57
US$ 20.86
US$ 27.19
US$ 24.41
US$ 21.76
